(lp0
S'IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action ... Yahoo Finance - Feb 4, 2017 LOS ANGELES, CA / ACCESSWIRE / March 8, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Regulus Therapeutics Inc.  . Investors, who purchased or otherwise&nbsp;...'
p1
aS'Regulus Therapeutics Inc.  Plunges 7.84% on March 20 Equities.com - Mar 20, 2017 Regulus Therapeutics Inc.  had a rough trading day for Monday March 20 as shares tumbled 7.84%, or a loss of $-0.1 per share, to close at $1.18.'
p2
aS'Regulus Therapeutics Inc.  Plunges 7.14% on March 15 Equities.com - Mar 15, 2017 Regulus Therapeutics Inc.  had a rough trading day for Wednesday March 15 as shares tumbled 7.14%, or a loss of $-0.1 per share, to close at $1.30.Regulus Therapeutics Inc.  Recent Ownership Changes - Post AnalystMost recent Trading report: Regulus Therapeutics Inc.  - Is stories'
p3
aS'RGLS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a ... PR Newswire  - Mar 13, 2017 NEW YORK, March 13, 2017 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Regulus Therapeutics Inc.'
p4
aS'Regulus Therapeutics Inc.  Soars 13.04% on March 08 Equities.com - Mar 8, 2017 Regulus Therapeutics Inc.  had a good day on the market for Wednesday March 08 as shares jumped 13.04% to close at $1.30.Regulus Therapeutics Inc.  Files Form 4 Insider Buying : William H ... - Energy IndexRegulus Therapeutics Inc.  added to 9 new portfolios - Post Analyst'
p5
aS"Regulus Reports Fourth Quarter 2016 Financial Results and Pipeline Update PR Newswire  - Mar 2, 2017 LA JOLLA, Calif., March 2, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. , a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth&nbsp;...Regulus Therapeutics'  CEO Paul Grint on Q4 2016 Results - Earnings Call ... - Seeking AlphaAnalyst Activity  Cantor Fitzgerald Reiterates Buy on Regulus Therapeutics ... - Market Exclusive"
p6
aS"A Look at 2 Trending Stocks: Regulus Therapeutics Inc. , CVR Refining ... Post Analyst - Mar 20, 2017 The company's consensus rating on Reuter's scale improved from 2.9 to 3 during a month. Analysts set a 12-month price target of $11.35 a share."
p7
aS"Sell-Side Analyst's Predictions: Regulus Therapeutics Inc. , RH  The USA Commerce - Mar 17, 2017 Regulus Therapeutics Inc.  share price increased in the last trading session with a previous 52-week high of $8.90."
p8
aS'Regulus Therapeutics Inc.: Regulus to Release Fourth Quarter and Full Year ... The Wall Street Transcript - Feb 23, 2017 23, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. , a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will release fourth quarter and full year 2016&nbsp;...Unusual Volume Spikes For: Regulus Therapeutics Inc.  - HugoPressRegulus Therapeutics Inc.  added to 9 new portfolios - Post Analyst'
p9
aS"Traders Checklist Stock: Regulus Therapeutics Inc.  Is stories - 21 hours ago RGLS's stock has received different recommendations from Financial Analysts, according to data provided by FactSet. 3 Months Ago, shares have been suggested as BUY from 5 and 0 issued SELL signal for the company's stock.2 told as a HOLD the stock."
p10
a.